Last updated 2026-07-23
- Raised $22M Series C led by Pontifax, Nov 2019
- Raised $4.5M Series A led by Pontifax, Jan 2016
- Raised $600k Seed round led by VLX Ventures, Nov 2014
Total raised
$27.1M
Last: Undisclosed Round 2025-10
Stage
Series C
Founded
2012
Headcount
5
HQ
Rehovot, Israel
Sector
Health Tech & Life Sciences
About
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary New Chemical Entity Drug, RZL-012, for aesthetic applications such as submental fat reduction and fat disorders like Dercum's disease. The drug is a single multi-site injection into subcutaneous fat that causes immediate fat cell death at the injection site, resulting in significant reduction of fat tissue for long periods. The company was founded in 2012 and is based in Rehovot, Israel, building on science developed at the Hebrew University in Jerusalem.
Funding history · 5 rounds · $27.1M total
2025-09
E Round
Undisclosed
★ Peregrine Ventures
2024-11
D Round
Undisclosed
★ Peregrine Ventures
2019-11
C Round
$22.0M
★ PontifaxCatalystWille AGQuark VentureShmuel CabillyDocor International Management
2016-01
A Round
$4.5M
★ Pontifax★ Docor International Management
2014-11
Seed
$600K
★ VLX Ventures★ Israel Innovation Authority
Q&A
- What is Raziel Therapeutics' primary drug candidate?
- Raziel Therapeutics' primary drug candidate is RZL-012, an injectable drug currently in preclinical development for targeted fat reduction.
- What is the mechanism of action for Raziel Therapeutics' RZL-012?
- RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process where necrotic fat tissue is replaced by fibrotic tissue, resulting in significant long-term fat tissue shrinkage.
- When was Raziel Therapeutics founded?
- Raziel Therapeutics was founded in August 2012.
- How many employees does Raziel Therapeutics currently have?
- Raziel Therapeutics has 1-10 employees.
- What was the total amount raised by Raziel Therapeutics to date?
- Raziel Therapeutics has raised a total of $27,100,000 USD.
- Which investors participated in Raziel Therapeutics' December 2019 funding round?
- The December 2019 funding round for Raziel Therapeutics included Pontifax.
- What is the current stage of Raziel Therapeutics' funding?
- Raziel Therapeutics is currently in its Series C funding stage.
- When did Raziel Therapeutics receive FDA approval for RZL-012 as an orphan drug?
- In November 2019, Raziel Therapeutics received FDA approval to develop RZL-012 as an orphan drug for Dercum's disease.
Team · 2
Alon Bloomenfeld
Founder · CEO & Co-Founder
Shmuel Ben-Sasson
Founder · Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticals
Business model
B2B
Tags
diabetestherapeuticsdrug-designobesitypharmaceuticalstreatmentschronic-patientspharma-companiesorphan-drugpatients
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | raziel-therapy.com |
|---|
Identifiers & details
| Legal name | Raziel Therapeutics (RT) Ltd. |
|---|---|
| Founded | 2012 |
| Employees (exact) | 5 |
Radar intelligence
Patents
| EPO | 9 |
|---|
Web history (Wayback)
| Domain | raziel-therapy.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514808955 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-08-12 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2023 |
| Active charges / liens | 1 |
| Registry events | 4 — violation (1), charge (1), people (1), other (1) |
| Registered address | הנגר 6 הוד השרון |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |
| 2025-08-21 | רישום שעבוד |
| 2025-12-14 | עדכון דירקטורים-עדכון מנהלים |
| 2025-12-07 | עדכון כתובת ו/או מען דיגיטלי |